Randomised controlled trial of azithromycin in smokers with asthma

European Respiratory Journal

Volumn 42, Issue 5, 2013, Pages 1412-1415

  Cameron, Euan J ^a   Chaudhuri, Rekha ^a   Mair, Frances ^b   McSharry, Charles ^a   Greenlaw, Nicola ^b   Weir, Christopher J ^b   Jolly, Lisa ^a   Donnelly, Iona ^a   Gallacher, Katie ^b   Morrison, Deborah ^b   Spears, Mark ^a   Evans, Tom J ^a   Anderson, Kenneth ^c   Thomson, Neil C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c CROSSHOUSE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; PLACEBO;

ASTHMA; DISEASE DURATION; FORCED EXPIRATORY VOLUME; HUMAN; LETTER; LUNG FUNCTION; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY TRACT INFECTION; SMOKING; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; AZITHROMYCIN; DOUBLE-BLIND METHOD; HUMANS; MIDDLE AGED; QUESTIONNAIRES; SMOKING; TOBACCO USE DISORDER; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887289351     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00093913     Document Type: Letter

References (13)

1. Thomson N, Chaudhuri R. Asthma in smokers: challenges and opportunities. Curr Opin Pulm Med 2009; 15: 39-45.
2. Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. Eur Respir J 2013; 41: 716-726.
3. Cameron EJ, McSharry C, Chaudhuri R, et al. Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clin Exp Allergy 2012; 42: 1302-1312.
4. Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 2013; 42: 239-251.
5. Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011; 37: 164-172.
6. Sutherland ER, King TS, Icitovic N, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010; 126: 747-753.
7. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. Thorax 2013; 68: 322-329.
8. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. GINA, 2010. www.ginasthma.org.
9. Greening A, Ind P, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-224.
10. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59-99.
11. Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003; 58: 339-343.
12. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-698.
13. Yamaya M, Azuma A, Takizawa H, et al. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J 2012; 40: 485-494.